FGFR1 and neoplasm: As shown in Figure 4A, treatment with ARPCA efficiently inhibited FGFR1 phosphorylation, Ki67+ proliferation index and CD31+ neovascularization in tumor grafts when compared to lesions harvested from ARPVA-treated animals, thus confirming the inhibitory effect of ARPCA on in vivo S115 cell growth and angiogenic potential.